# NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial

> **NCT06066437** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 6 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Arm A: 177Lu rhPSMA-10.1
- **DRUG:** Arm B: 177Lu rhPSMA-10.1 plus Degarelix

## Key facts

- **NCT ID:** NCT06066437
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-29
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06066437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06066437, "NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06066437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*